Tourmaline Bio, Inc.
TRMLDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001827506
Tourmaline Bio, Inc. was delisted in 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 134
- Q3 2025, +25 vs. previous quarter
- 13F value
- $1.03B
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Superinvestors holding TRML, Q3 2025
No superinvestor reported holding TRML at the end of Q3 2025.
Latest insider trades
Open-market purchases and sales by Tourmaline Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 22, 2024 (view filing) | Aug 21 | 1 day | Kulkarni Sandeep ChidambarCEO | PPurchase | +1.78K | $14.85 | +$26.4K | +34.1%7.00K after | |
| Aug 20, 2024 (view filing) | Aug 16 | 4 days | Kulkarni Sandeep ChidambarCEO | PPurchase | +5.22K | $13.79 | +$72.0K | New position5.22K after | |
| Jan 31, 2024 (view filing) | Jan 29 | 2 days | McDade MarkDirector | PPurchase | +100.0K | $32.50 | +$3.25M | +28.7%448.4K after | |
| Nov 20, 2023 (view filing) | Nov 17 | 3 days | Kulkarni Sandeep ChidambarCEO | PPurchase | +4.00K | $16.99 | +$68.0K | +0.6%729.7K after | |
| Nov 20, 2023 (view filing) | Nov 17 | 3 days | Thiara ParvinderDirector | PPurchase | +1.00K | $17.31 | +$17.3K | +1.2%83.8K after | |
| Oct 27, 2023 (view filing) | Oct 25-27 | 2 days | Castelein CaleyDirector | PPurchase | +20.0K | $14.03 | +$280.6K | +4.0%516.5K after | 2 lots |
| Oct 26, 2023 (view filing) | Oct 24-26 | 2 days | Kulkarni Sandeep ChidambarCEO | PPurchase | +9.65K | $11.49 | +$110.9K | +1.3%725.7K after | 2 lots |
| Oct 26, 2023 (view filing) | Oct 24 | 2 days | Kantoff AaronDirector | PPurchase | +7.50K | $11.86 | +$89.0K | +19.8%45.4K after | |
| Oct 26, 2023 (view filing) | Oct 24-25 | 2 days | Thiara ParvinderDirector | PPurchase | +7.00K | $11.08 | +$77.5K | +9.2%82.8K after | 2 lots |
| Jun 14, 2023 (view filing) | Jun 12-14 | 2 days | Ildstad SuzanneDirector | SSale | −44.0K | $2.55 | −$112.3K | −1.2%3.77M after | 3 lots10b5-1 |
Top 10 13F holders, Q3 2025
The largest institutional positions in Tourmaline Bio, Inc. at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 2,555,555 | $122.2M | 1.58% | 00.0% | Unchanged |
| QVT Financial LP | 2,154,653 | $103.1M | 11.44% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,517,777 | $72.6M | 0.00% | −116,165−7.1% | Reduced |
| TCG Crossover Management, LLC | 1,311,783 | $62.7M | 3.09% | −165,810−11.2% | Reduced |
| Pfizer Inc | 1,272,214 | $60.8M | 13.91% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,165,607 | $55.8M | 0.00% | −41,428−3.4% | Reduced |
| FIL Ltd | 1,027,690 | $49.2M | 0.04% | +1,027,690 | New |
| Magnetar Financial LLC | 966,129 | $46.2M | 0.28% | +966,129 | New |
| Qiming U.S. Ventures Management, LLC | 741,691 | $35.5M | 63.76% | 00.0% | Unchanged |
| Vivaldi Asset Management, LLC | 695,757 | $33.3M | 2.15% | +695,757 | New |